JP2017536398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536398A5 JP2017536398A5 JP2017529604A JP2017529604A JP2017536398A5 JP 2017536398 A5 JP2017536398 A5 JP 2017536398A5 JP 2017529604 A JP2017529604 A JP 2017529604A JP 2017529604 A JP2017529604 A JP 2017529604A JP 2017536398 A5 JP2017536398 A5 JP 2017536398A5
- Authority
- JP
- Japan
- Prior art keywords
- solid dispersion
- arn
- hpmcas
- formulation
- weight ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007962 solid dispersion Substances 0.000 claims description 35
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000006104 solid solution Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 11
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229960004103 abiraterone acetate Drugs 0.000 claims 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical group C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000010971 suitability test Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196594 | 2014-12-05 | ||
| EP14196594.7 | 2014-12-05 | ||
| PCT/US2015/063661 WO2016090098A1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020076516A Division JP7174006B2 (ja) | 2014-12-05 | 2020-04-23 | 抗癌性組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536398A JP2017536398A (ja) | 2017-12-07 |
| JP2017536398A5 true JP2017536398A5 (cg-RX-API-DMAC7.html) | 2019-01-24 |
| JP6937692B2 JP6937692B2 (ja) | 2021-09-22 |
Family
ID=52006906
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529604A Active JP6937692B2 (ja) | 2014-12-05 | 2015-12-03 | 抗癌性組成物 |
| JP2020076516A Active JP7174006B2 (ja) | 2014-12-05 | 2020-04-23 | 抗癌性組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020076516A Active JP7174006B2 (ja) | 2014-12-05 | 2020-04-23 | 抗癌性組成物 |
Country Status (29)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3305285T (lt) | 2012-09-26 | 2020-12-10 | Aragon Pharmaceuticals, Inc. | Anti-androgenai, skirti gydyti nametastazavusį kastracijai atsparų prostatos vėžį |
| PL3226843T3 (pl) | 2014-12-05 | 2021-12-13 | Aragon Pharmaceuticals, Inc. | Kompozycje przeciwnowotworowe |
| CN114886852A (zh) | 2014-12-05 | 2022-08-12 | 阿拉贡药品公司 | 抗癌组合物 |
| CA3079135A1 (en) | 2017-10-16 | 2019-04-25 | Arturo Molina | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| WO2020144646A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Apalutamide dispersed in applesauce for treating prostate cancer |
| CA3143199A1 (en) | 2019-01-30 | 2020-08-06 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| US20220160695A1 (en) | 2019-01-30 | 2022-05-26 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| EP3811932A1 (en) | 2019-10-22 | 2021-04-28 | Zentiva K.S. | Dosage form of apalutamide |
| EP4054572A1 (en) | 2019-11-04 | 2022-09-14 | Aragon Pharmaceuticals, Inc. | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| WO2022049523A1 (en) | 2020-09-04 | 2022-03-10 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023122842A1 (es) * | 2021-12-31 | 2023-07-06 | Gador Limitada | Proceso para la preparación de apalutamida, intermediarios de sintesis y la dispersion solida amorfa que la contiene |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| CN116183787A (zh) * | 2022-12-26 | 2023-05-30 | 郑州德迈药业有限公司 | 醋酸羟丙甲纤维素琥珀酸酯在阿帕他胺溶出检测中的应用以及检测方法 |
| CN121038790A (zh) | 2023-03-16 | 2025-11-28 | 拜耳消费者护理股份有限公司 | 用于治疗激素敏感性前列腺癌生化复发患者的雄激素受体拮抗剂 |
| WO2025153768A1 (en) * | 2024-01-18 | 2025-07-24 | Nanoform Finland Oyj | Composition comprising crystalline nanosized apalutamide |
| WO2025174375A1 (en) * | 2024-02-15 | 2025-08-21 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993020097A1 (en) | 1992-03-31 | 1993-10-14 | British Technology Group Ltd. | 17-substituted steroids useful in cancer treatment |
| DK0901786T3 (da) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
| CA2400845A1 (en) | 2000-02-21 | 2001-08-23 | Takeda Chemical Industries, Ltd. | Sustained-release preparation of physiologically active compound slightly soluble in water and production process and use of the same |
| DE60206889T2 (de) | 2001-02-27 | 2006-07-27 | Astrazeneca Ab | Pharmazeutische formulierung enthaltend bicalutamid |
| BR0208421A (pt) | 2001-04-02 | 2004-03-30 | Astrazeneca Ab | Formulação farmacêutica para administração a um paciente através das mucosas, dose farmacêutica diária, dispersão sólida, uso de pvp em dispersão sólida com 4'-ciano-alfa', alfa', alfa'-trifluoro-3-(4-fluoro fenilsulfonil)-2-hidróxi-2-metilpropiono-m-toluidet o, e, métodos para aumentar a estabilidade em armazenagem, a biodisponibilidade da droga e para reduzir a variação de concentrações de plasma do 4'-ciano-alfa', alfa', alfa',-trifluoro-3-(4-fluorofenilsulfonil)-2-hidróxi-2 -metilpropiono-m-toluideto entre pacientes |
| SK15732003A3 (sk) * | 2001-06-22 | 2005-01-03 | Pfizer Products Inc. | Farmaceutické kompozície zahrnujúce liečivá s nízkou rozpustnosťou a/alebo liečivá citlivé na kyselinu a neutralizované kyslé polyméry |
| SE0103424D0 (sv) * | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
| WO2003063821A2 (en) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| WO2003077827A1 (en) | 2002-03-19 | 2003-09-25 | Nippon Shinyaku Co., Ltd. | Process for producing drug solid dispersion |
| CA2549572A1 (en) | 2003-12-15 | 2005-06-23 | Council Of Scientific & Industrial Research | Taste masked pharmaceutical compositions comprising bitter drug and ph sensitive polymer |
| GB0502790D0 (en) | 2005-02-10 | 2005-03-16 | Univ London Pharmacy | Solid dispersion of hydrophobic bioactive |
| KR101332924B1 (ko) | 2005-05-13 | 2013-11-26 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴히단토인 화합물 |
| SI3412290T1 (sl) | 2006-03-27 | 2021-09-30 | The Regents Of The University Of California | Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji |
| DK2414356T3 (en) | 2009-04-03 | 2015-12-14 | Hoffmann La Roche | PROPAN-1-sulfonic acid {3- [5- (4-CHLORO-PHENYL) -1H-pyrrolo [2,3-b] pyridine-3- carbonyl] -2,4-difluorophenyl) -AMIDSAMMENSÆTNINGER AND USES THEREOF |
| US9108944B2 (en) | 2010-02-16 | 2015-08-18 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| CN102525876B (zh) | 2010-12-15 | 2014-03-12 | 西安力邦医药科技有限责任公司 | 阿司匹林固体分散体、其制备方法、药物组合物和用途 |
| EP3333153A1 (en) | 2011-06-15 | 2018-06-13 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| US20150037407A1 (en) | 2012-03-21 | 2015-02-05 | Emphascience, Inc. | Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy |
| WO2013152342A1 (en) * | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| MY187500A (en) | 2012-06-07 | 2021-09-24 | Aragon Pharmaceuticals Inc | Crystalline forms of an androgen receptor modulator |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| KR102138544B1 (ko) * | 2012-08-24 | 2020-07-28 | 다우 글로벌 테크놀로지스 엘엘씨 | 신규한 하이드록시알킬 메틸 셀룰로즈 아세테이트 석시네이트 |
| DK3725778T3 (da) | 2012-09-11 | 2021-09-20 | Medivation Prostate Therapeutics Llc | Formuleringer af enzalutamid |
| US9977033B2 (en) | 2012-09-11 | 2018-05-22 | The Board Of Regents Of The University Of Texas System | Methods for assessing cancer recurrence |
| LT3305285T (lt) * | 2012-09-26 | 2020-12-10 | Aragon Pharmaceuticals, Inc. | Anti-androgenai, skirti gydyti nametastazavusį kastracijai atsparų prostatos vėžį |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| EA028009B1 (ru) | 2013-01-22 | 2017-09-29 | Ф.Хоффманн-Ля Рош Аг | Фармацевтическая композиция с улучшенной биодоступностью |
| KR20180021932A (ko) | 2013-03-15 | 2018-03-05 | 아이슈티카 인코포레이티드 | 아비라테론 아세테이트 제제 |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| BR112016002970A2 (pt) * | 2013-08-12 | 2017-09-12 | Tokai Pharmaceuticals Inc | biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio |
| US9566280B2 (en) | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| AU2015215000B2 (en) * | 2014-02-05 | 2017-10-19 | Lek Pharmaceuticals D.D. | Solid pharmaceutical compositions of androgen receptor antagonists |
| TWI831347B (zh) | 2014-08-08 | 2024-02-01 | 日商中外製藥股份有限公司 | 包含４環性化合物的非晶質體之固體分散體及製劑 |
| CA2969661C (en) | 2014-12-05 | 2023-04-25 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| CN114886852A (zh) | 2014-12-05 | 2022-08-12 | 阿拉贡药品公司 | 抗癌组合物 |
| PL3226843T3 (pl) | 2014-12-05 | 2021-12-13 | Aragon Pharmaceuticals, Inc. | Kompozycje przeciwnowotworowe |
| MX2018014846A (es) | 2016-06-03 | 2019-03-14 | Aragon Pharmaceuticals Inc | Composiciones antineoplasicas. |
| KR20210023987A (ko) | 2018-06-20 | 2021-03-04 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | Arn-509의 결정형, 그 제조방법 및 그 용도 |
| EP3811932A1 (en) | 2019-10-22 | 2021-04-28 | Zentiva K.S. | Dosage form of apalutamide |
-
2015
- 2015-12-03 CN CN202210133724.8A patent/CN114886852A/zh active Pending
- 2015-12-03 HR HRP20241719TT patent/HRP20241719T1/hr unknown
- 2015-12-03 MA MA41107A patent/MA41107B1/fr unknown
- 2015-12-03 CA CA2969656A patent/CA2969656A1/en active Pending
- 2015-12-03 CR CR20170216A patent/CR20170216A/es unknown
- 2015-12-03 MX MX2017007203A patent/MX387933B/es unknown
- 2015-12-03 ES ES15817641T patent/ES2996833T3/es active Active
- 2015-12-03 AU AU2015358490A patent/AU2015358490B2/en active Active
- 2015-12-03 KR KR1020207035390A patent/KR20200141533A/ko not_active Ceased
- 2015-12-03 BR BR112017011788A patent/BR112017011788A2/pt not_active Application Discontinuation
- 2015-12-03 US US15/533,188 patent/US20170360754A1/en not_active Abandoned
- 2015-12-03 EP EP24202355.4A patent/EP4494636A3/en active Pending
- 2015-12-03 EA EA201791222A patent/EA201791222A1/ru unknown
- 2015-12-03 JP JP2017529604A patent/JP6937692B2/ja active Active
- 2015-12-03 WO PCT/US2015/063661 patent/WO2016090098A1/en not_active Ceased
- 2015-12-03 UA UAA201707020A patent/UA120950C2/uk unknown
- 2015-12-03 SG SG11201704267VA patent/SG11201704267VA/en unknown
- 2015-12-03 NZ NZ770528A patent/NZ770528A/en unknown
- 2015-12-03 EP EP15817641.2A patent/EP3226841B1/en active Active
- 2015-12-03 RS RS20241412A patent/RS66323B1/sr unknown
- 2015-12-03 KR KR1020177018239A patent/KR102348320B1/ko active Active
- 2015-12-03 PL PL15817641.2T patent/PL3226841T3/pl unknown
- 2015-12-03 MD MDE20170152T patent/MD3226841T2/ro unknown
- 2015-12-03 CN CN201580066233.4A patent/CN106999431B/zh active Active
- 2015-12-03 HU HUE15817641A patent/HUE069689T2/hu unknown
- 2015-12-03 SM SM20240518T patent/SMT202400518T1/it unknown
- 2015-12-04 TW TW104140822A patent/TWI702966B/zh active
- 2015-12-04 TW TW109112959A patent/TWI754258B/zh active
- 2015-12-04 AR ARP150103982A patent/AR102926A1/es not_active Application Discontinuation
-
2017
- 2017-05-16 IL IL252323A patent/IL252323B/en active IP Right Grant
- 2017-05-25 PH PH12017500964A patent/PH12017500964A1/en unknown
- 2017-05-29 CL CL2017001371A patent/CL2017001371A1/es unknown
- 2017-06-05 CO CONC2017/0005572A patent/CO2017005572A2/es unknown
- 2017-06-05 MX MX2021013965A patent/MX2021013965A/es unknown
-
2020
- 2020-04-23 JP JP2020076516A patent/JP7174006B2/ja active Active
- 2020-12-29 IL IL279833A patent/IL279833B/en unknown
-
2021
- 2021-03-30 AU AU2021201979A patent/AU2021201979B2/en active Active
-
2023
- 2023-03-29 US US18/192,244 patent/US20230233529A1/en not_active Abandoned
- 2023-05-02 AU AU2023202710A patent/AU2023202710A1/en not_active Abandoned
-
2024
- 2024-05-10 US US18/660,698 patent/US12303493B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536398A5 (cg-RX-API-DMAC7.html) | ||
| JP2017536401A5 (cg-RX-API-DMAC7.html) | ||
| Li et al. | Quinolizidine alkaloids derivatives from Sophora alopecuroides Linn: Bioactivities, structure-activity relationships and preliminary molecular mechanisms | |
| HRP20211140T1 (hr) | Pripravci protiv raka | |
| HRP20241719T1 (hr) | Antitumorske smjese | |
| JP2019517497A5 (cg-RX-API-DMAC7.html) | ||
| HRP20201902T1 (hr) | Pripravci protiv raka | |
| Gullapalli | Soft gelatin capsules (softgels) | |
| Shalini et al. | Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on? | |
| CN105611918B (zh) | 含有他达拉非的口腔崩解型膜制剂及其制备方法 | |
| JP2017536407A5 (cg-RX-API-DMAC7.html) | ||
| JP2012236837A5 (cg-RX-API-DMAC7.html) | ||
| JP2018504443A5 (cg-RX-API-DMAC7.html) | ||
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| WO2024189607A1 (en) | Methods and bioavailable highly permeable compounds for diseases treatment | |
| JP2012025755A5 (cg-RX-API-DMAC7.html) | ||
| JP2011225600A5 (cg-RX-API-DMAC7.html) | ||
| RU2014145557A (ru) | Комбинированный состав, содержащий многокомпонентную сфероидальную таблетку (мкст), заключенную в твердую капсулу, и способ его приготовления | |
| JP2014523445A5 (cg-RX-API-DMAC7.html) | ||
| WO2011107855A3 (en) | Sustained release oral liquid suspension dosage form | |
| JP2016539953A5 (cg-RX-API-DMAC7.html) | ||
| JP2014516080A5 (cg-RX-API-DMAC7.html) | ||
| HRP20191366T4 (hr) | Injekcijski pripravak | |
| JP6470257B2 (ja) | 分散安定化剤としてポリエチレングリコール系高分子及び／またはビニルピロリドン系高分子を含むタダラフィル遊離塩基含有フィルム剤形 |